Redeye updates its estimates and valuation following ADDvise releasing its Q2 2024 report, which featured expectedly soft figures. Top-line and adjusted profitability figures came in below our estimates, though organic growth will likely recover in Q4 2024e and onwards. Further, the company’s recent sudden CEO transition will likely require some time to regain investor confidence as stability returns. We nudge down our estimates and valuation.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/